Image 5_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…Background<p>Esophageal cancer continues to pose a significant public health challenge worldwide. However, the extent to which advancements in treatment have reduced mortality at the population level remains unclear. …”

Image 6_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…Background<p>Esophageal cancer continues to pose a significant public health challenge worldwide. However, the extent to which advancements in treatment have reduced mortality at the population level remains unclear. …”

Image 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…Background<p>Esophageal cancer continues to pose a significant public health challenge worldwide. However, the extent to which advancements in treatment have reduced mortality at the population level remains unclear. …”

Data Sheet 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…Background<p>Esophageal cancer continues to pose a significant public health challenge worldwide. However, the extent to which advancements in treatment have reduced mortality at the population level remains unclear. …”

Image 4_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…Background<p>Esophageal cancer continues to pose a significant public health challenge worldwide. However, the extent to which advancements in treatment have reduced mortality at the population level remains unclear. …”

Data Sheet 2_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…Background<p>Esophageal cancer continues to pose a significant public health challenge worldwide. However, the extent to which advancements in treatment have reduced mortality at the population level remains unclear. …”

Effects of liposomal bupivacaine (LB) and provider experience with LB on service utilization, clinical outcomes, and Medicare expenditures among fee-for-service (FFS) beneficiaries by Sarmistha Pal (13348959)

“…Since provider LB use rate can provide better post-surgical outcomes for Medicare patients while reducing overall total Medicare costs, CMS policies could support increased provider LB use by facilitating provider access to LB to have a meaningful impact on reducing opioid consumption and decreasing Medicare expenditures.</p><p></p> <p>Liposomal bupivacaine (LB) represents a significant advancement in postoperative pain management, with studies demonstrating its ability to reduce opioid consumption and improve recovery outcomes. …”

Data Sheet 1_Global, regional, and national burdens of endometriosis from 1990 to 2021: a trend analysis.docx by Hailan Yan (18174379)

“…Background<p>Endometriosis is a common, chronic, estrogen-dependent gynecological disorder that significantly affects patients’ quality of life. However, the disease burden and its trends may be undergoing significant changes, and comprehensive data on this issue are currently lacking. …”

Data Sheet 1_Risk factors of low bone mass in young patients with transfusion-dependent beta-thalassemia.docx by Wei Zhang (405)

“…Without height-adjusted BMD correction, the overall prevalence was 31.6% (33.4% in the 5-19-year subgroup), which significantly decreased to 15.8% in the 5-19-year subgroup after height-adjusted correction, highlighting that traditional BMD assessments may overestimate risk due to unaccounted short stature. …”

Dataset study -Impact of Technical Standardization on Pneumothorax and Chest Tube Insertion Rates: A Retrospective Learning Curve Analysis of CT-Guided Lung Biopsies by Rosa Alba Pugliesi (20766383)

“…<p dir="ltr">This study retrospectively evaluates whether improved needle angulation and procedural standardization have reduced pneumothorax and chest tube insertion rates over time in CT-guided lung biopsies, showing significant decreases linked to technical advancements and enhanced operator knowledge.…”

Table 4_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Supplementary file 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Table 2_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Table 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Table 3_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Table 7_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Supplementary file 2_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Image 6_Burden of pulmonary arterial hypertension in children globally, regionally, and nationally (1990–2021): results from the global burden of disease study.tif by Lili Deng (152262)

“…</p>Results<p>The findings indicate a stable prevalence rate globally, with a slight increase in the absolute number of cases. Significantly, reductions were observed in both mortality and disability-adjusted life years (DALYs) associated with pediatric PAH, with mortality decreasing by 57.66% and DALYs by 63.59% over the study period, indicating progress in mitigating the disease burden. …”

Image 3_Burden of pulmonary arterial hypertension in children globally, regionally, and nationally (1990–2021): results from the global burden of disease study.tif by Lili Deng (152262)

“…</p>Results<p>The findings indicate a stable prevalence rate globally, with a slight increase in the absolute number of cases. Significantly, reductions were observed in both mortality and disability-adjusted life years (DALYs) associated with pediatric PAH, with mortality decreasing by 57.66% and DALYs by 63.59% over the study period, indicating progress in mitigating the disease burden. …”

Image 1_Burden of pulmonary arterial hypertension in children globally, regionally, and nationally (1990–2021): results from the global burden of disease study.tif by Lili Deng (152262)

“…</p>Results<p>The findings indicate a stable prevalence rate globally, with a slight increase in the absolute number of cases. Significantly, reductions were observed in both mortality and disability-adjusted life years (DALYs) associated with pediatric PAH, with mortality decreasing by 57.66% and DALYs by 63.59% over the study period, indicating progress in mitigating the disease burden. …”